Log In
Print this Print this

AV-203, CAN-017

  Manage Alerts
Collapse Summary General Information
Company Aveo Pharmaceuticals Inc.
DescriptionErb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)-targeted antibody
Molecular Target Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerBoehringer Ingelheim GmbH;
Canbridge Life Sciences Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today